Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

BACKGROUND: Revefenacin is a long-acting muscarinic antagonist that was recently approved for the nebulized treatment of chronic obstructive pulmonary disease (COPD). Although shorter duration studies have documented the efficacy of revefenacin in COPD, longer-term efficacy has not been described. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Donohue, James F., Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N., Moran, Edmund J., Crater, Glenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822411/
https://www.ncbi.nlm.nih.gov/pubmed/31666076
http://dx.doi.org/10.1186/s12931-019-1187-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822411/
https://www.ncbi.nlm.nih.gov/pubmed/31666076
http://dx.doi.org/10.1186/s12931-019-1187-7

Ejemplares similares